Q-omics provides the consensus-scored NPBWR2 profile across patient tissues and cancer cell-line models. NPBWR2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, NPBWR2 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, NPBWR2 protein abundance shows 26,850 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUSC, KIRC, and GBM as cancer lineages where NPBWR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPBWR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPBWR2 survival associations across molecular data types. NPBWR2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPBWR2 RNA expression–survival associations across cancer types. High NPBWR2 expression shows unfavorable associations in LUSC, THCA, ACC, TGCT and OV, but favorable associations in DLBC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for NPBWR2 RNA expression.
This table summarizes NPBWR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NPBWR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPBWR2 shows lower tumor expression in KIRC and higher tumor expression in THCA, BLCA and LUAD. The KIRC box plot shows higher NPBWR2 RNA expression in normal versus tumor tissue (log2 FC = −0.010, t-test p = .002).
This table shows molecular features associated with NPBWR2 in patient tissues and cancer cell lines. In patient samples, NPBWR2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NPBWR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
